cognitive cybersecurity intelligence

News and Analysis

Search

VISEN growth hormone deficiency trial results announced

VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.

The data showed…

Source: www.labiotech.euRead more

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts